Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Name: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
License: Public Domain

National Cancer Institute (NCI)

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

metastatic colorectal cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 136309
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.